Author
Moinet Gerard
Bio: Moinet Gerard is an academic researcher from Merck & Co.. The author has contributed to research in topics: Aryl. The author has an hindex of 2, co-authored 3 publications receiving 22 citations.
Topics: Aryl
Papers
More filters
Patent•
05 Aug 1997TL;DR: In this article, a pharmaceutical composition containing, as active principle, a compound of formula (a) in which groups A and B are selected independently of each other among: a monocyclic, bi-cyclic or tricyclic aryl group having 6 to 14 carbon atoms; a heteroaraomatic group selected among the pyridyl, pyrimidyl and pyrrolyl, furyl and thienyl groups.
Abstract: The invention concerns a pharmaceutical composition containing, as active principle, a compound of formula (a) in which groups A and B are selected independently of each other among: a mono-cyclic, bi-cyclic or tri-cyclic aryl group having 6 to 14 carbon atoms; a heteroaraomatic group selected among the pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups; an alkyl group having 1 to 14 carbon atoms; a cycloalkyl group having 5 to 8 carbon atoms; a saturated heterocyclic group selected among the tetrahydrofuryl, tetrahydropyrranyl, piperidinyl and pyrrolidinyl groups; its solvate or a salt of this acid with a pharmaceutically acceptable base.
16 citations
Patent•
10 Apr 2002
TL;DR: In this paper, the authors present a pharmaceutical composition comprising, as active principle, a compound of formula: in which the groups A and B are chosen, independently of each other, from: a mono-, bi- or tricyclic aryl group having from 6 to 14 carbon atoms; a heteroaromatic group chosen from pyridyl, pyrimidyl and pyrrolyl, furyl and thienyl groups.
Abstract: PCT No. PCT/EP97/04252 Sec. 371 Date Feb. 2, 1999 Sec. 102(e) Date Feb. 2, 1999 PCT Filed Aug. 5, 1997 PCT Pub. No. WO98/07681 PCT Pub. Date Feb. 26, 1998The present invention relates to a pharmaceutical composition comprising, as active principle, a compound of formula: in which the groups A and B are chosen, independently of each other, from: a mono-, bi- or tricyclic aryl group having from 6 to 14 carbon atoms; a heteroaromatic group chosen from pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups; an alkyl group having from 1 to 14 carbon atoms; a cycloalkyl group having from 5 to 8 carbon atoms; a saturated heterocyclic group chosen from tetrahydrofuryl, tetrahydropyranyl, piperidyl and pyrrolidinyl groups; to its solvate or to a salt of this acid with a pharmaceutically acceptable base. Figures: none.
6 citations
Patent•
05 Aug 1997
TL;DR: In this paper, a composition pharmaceutique comprenant, a titre de principe actif, un compose de formule (I) dans laquelle les groupes A and B sont choisis independamment l'un de l'autre parmi: un groupe aryle mono-, bi- ou tricyclique ayant de 6 a 14 atomes de carbone; un groupes pyridyle, pyrimidyl, pyrrolyle, furyle et thienyle; un
Abstract: La presente invention concerne une composition pharmaceutique comprenant, a titre de principe actif, un compose de formule (I) dans laquelle les groupes A et B sont choisis independamment l'un de l'autre parmi: un groupe aryle mono-, bi- ou tricyclique ayant de 6 a 14 atomes de carbone; un groupe heteroaromatique choisi parmi les groupes pyridyle, pyrimidyle, pyrrolyle, furyle et thienyle; un groupe alcoyle ayant de 1 a 14 atomes de carbone; un groupe cycloalcoyle ayant de 5 a 8 atomes de carbone; un groupe heterocyclique sature choisi parmi les groupes tetrahydrofuryle, tetrahydropyrranyle, piperidinyle et pyrrolidinyle; son solvate ou un sel de cet acide avec une base pharmaceutiquement acceptable.
Cited by
More filters
Patent•
22 Jan 2007
TL;DR: In this article, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
105 citations
Patent•
31 Oct 2003
TL;DR: In this paper, chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related dis-eases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 dia-betes (NIDDM), impaired glucose tolerance, dyslip-idemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of can-cer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such
Abstract: This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related dis-eases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 dia-betes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslip-idemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of can-cer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.
31 citations
Patent•
18 Dec 2003TL;DR: In this paper, the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes was discussed.
Abstract: The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes.
11 citations
Patent•
09 Feb 2004
TL;DR: In this paper, compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
8 citations
Patent•
06 Nov 2002
TL;DR: In this article, a pharmaceutical composition comprising, as active principles, metformin, optionally in the form of one of its pharmaceutically acceptable salts, and a 4-oxobutanoic acid, in combination with one or more pharmaceutical excipients, was presented.
Abstract: The present invention relates to a pharmaceutical composition comprising, as active principles, metformin, optionally in the form of one of its pharmaceutically acceptable salts, and a 4-oxobutanoic acid, in combination with one or more pharmaceutically acceptable excipients. These compositions are particularly suitable for treating non-insulin-dependent diabetes.
6 citations